Nanocarriers for AKT siRNA Based Gene Therapy

Editorial

Austin J Biotechnol Bioeng. 2016; 3(2): 1061.

Nanocarriers for AKT siRNA Based Gene Therapy

Dubey P1 and Gopinath P1,2*

1Centre for Nanotechnology, Indian Institute of Technology Roorkee, India

2Department of Biotechnology, Indian Institute of Technology Roorkee, India

*Corresponding author: Gopinath P, Department of Biotechnology, Nanobiotechnology Laboratory, Indian Institute of Technology, Roorkee, Uttarakhand-247667, India

Received: April 27, 2016; Accepted: May 03, 2016; Published: May 05, 2016

Editorial

In the past few decades significant attention has drawn for gene silencing strategies based on RNA interference (RNAi)-mediated knock down of oncogene targeted cancer therapy [1]. RNAi refers to a method, where specific protein suppression could be achieved by delivery of double stranded short (20-25bp) interfering RNA (siRNA) [2]. However, the successful RNAi mediated gene therapy depends upon effective intracellular delivery of siRNA either as preformed siRNA or in conjugation with expressing plasmid vector and the efficient knock-down of oncogene transcripts [3].

Among various oncogenic targets, AKT⁄ Protein Kinase B (PKB) remains the central player in cell signaling pathways, altering cell survival and death [4]. Its activation leads to apoptotic resistance in cells, support cell survival, growth, and migration, energy metabolism and angiogenesis. It is evident from various studies that AKT perturbations plays an important part in tumorigenesis, [5] based on constitutive and increased expression of various AKT isoforms in diverse cancers, the inactivation of antagonists such as Phosphatase Tensin Homolog (PTEN), or mRNA over expression [6,7]. Its antiapoptotic action accounts for cell transforming ability and drug resistance in cancer cells against various chemotherapeutic agents [8]. Hence, AKT appears to play a pivotal role in the growth and tumor cells survival. Activation of Phosphatidylinositol 3-Kinase (PI3K)-/ AKT due to genetic alteration leads to chemotherapeutic insensitivity in diverse cancer preclinical and clinical trials [7,9]. Its dysregulation showed profound effect on the sensitivity of doxorubicin and 4-hydroxyl tamoxifen toward breast cancer chemotherapeutics [10]. Furthermore, characteristic AKT activation has been observed in various human tumor malignancies thus resulting in unfortunate predictive results [11,12]. Three AKT isoforms: AKT1⁄PKBα, AKT2⁄PKBβ, and AKT3⁄PKBc namely found in mammalian tissues, among which AKT1 and AKT2 has been found to be ubiquitously expressed in all type tissues observed and upregulated in various transformed tissues [5]. All these isoforms share amino acid homology closely and gets activated by PI3K-dependent pathway [2].

Consequently, AKT regulation possesses tremendous therapeutic attention and can be accomplished by successful delivering of AKTsiRNA. But for successful AKT-siRNA delivery, capable and safe nanocarrier is utmost necessity, and has appeared as major hurdle in siRNA based therapeutics. Though the RNAi is naturally occurring process in cells which provide all necessary components including the formation of RNA-Induced Silencing Complex (RISC) induces dicer endonuclease mediated cleavage of mRNA as showed in Figure 1a [13]. However the delivery of therapeutic siRNA is essential for induction of RNAi. Thus difficulties in the systemic delivery of siRNA to targeted tissues due to poor intracellular uptake, immunogenic response and limited blood stability hinders the siRNA therapeutics [14]. Additionally, delivery of siRNA to the target tumor site has been another hurdle in gene therapy. Furthermore, the bare siRNAs do not able to easily cross the cell membrane due to their negative charge and size [15].

Citation: Dubey P and Gopinath P. Nanocarriers for AKT siRNA Based Gene Therapy. Austin J Biotechnol Bioeng. 2016; 3(2): 1061. ISSN: 2378-3036